TP53 mutations in malignant and premalignant Barrett's esophagus

Area of Science:

• Gastroenterology
• Oncology
• Molecular Biology

Background:

• Barrett's esophagus surveillance requires improved markers for neoplastic progression beyond dysplasia.
• Identifying high-risk patients is crucial for effective endoscopic surveillance strategies.

Purpose of the Study:

• To evaluate TP53 mutational analysis for identifying patients with Barrett's esophagus at the highest risk of developing adenocarcinoma.
• To assess the utility of TP53 mutations in stratifying risk for endoscopic surveillance.

Main Methods:

• TP53 mutational analysis using single-strand conformation polymorphism and DNA sequencing.
• Analysis performed on premalignant and malignant tissues from esophagectomy patients and surveillance program participants.
• Longitudinal follow-up of surveillance patients for a median of 5 years.

Main Results:

• TP53 mutations were found in 33% of esophageal adenocarcinomas and 4% of premalignant Barrett's esophagus.
• Identical TP53 mutations were observed in adjacent dysplasia and carcinoma.
• TP53 mutations were detected in premalignant tissue prior to high-grade dysplasia or adenocarcinoma development.
• No patients without TP53 mutations progressed to high-grade dysplasia or adenocarcinoma.

Conclusions:

• TP53 mutational analysis can detect neoplastic progression before high-grade dysplasia or carcinoma in Barrett's esophagus.
• TP53 mutation status is a potential biomarker for stratifying adenocarcinoma risk in Barrett's esophagus patients.
• This method may enhance the efficacy of endoscopic surveillance for Barrett's esophagus.